deltatrials
Completed NA INTERVENTIONAL 3-arm NCT00587483

Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation

The Use of Amiodarone vs. Lidocaine and Placebo for the Prevention of Ventricular Fibrillation After Myocardial Reperfusion During Cardiopulmonary Bypass

Sponsor: Mayo Clinic

Updated 10 times since 2017 Last updated: Aug 9, 2011 Started: Nov 30, 2007 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00587483, this NA trial focuses on Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery and remains completed. Sponsored by Mayo Clinic, it has been updated 10 times since 2007, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Study Description(click to expand)

This was a prospective, randomized, double blinded study in which patients undergoing cardiopulmonary bypass with aortic cross clamping were randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. Specifically, we will test the hypothesis that amiodarone administration decreases the incidence of ventricular fibrillation, the number of defibrillation attempts and the total energy and current required for defibrillation should ventricular fibrillation occur.

This was a prospective, randomized, double blinded study in which patients undergoing cardiopulmonary bypass with aortic cross clamping were randomly assigned to receive amiodarone, lidocaine, or saline placebo prior to removal of the aortic cross clamp. Specifically, we will test the hypothesis that amiodarone administration decreases the incidence of ventricular fibrillation, the number of defibrillation attempts and the total energy and current required for defibrillation should ventricular fibrillation occur.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Sep 2020 · 27 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2023 — Jul 2024 [monthly]

    Completed NA

  4. Dec 2022 — Jan 2023 [monthly]

    Completed NA

  5. Dec 2021 — Dec 2022 [monthly]

    Completed NA

Show 5 earlier versions
  1. Jan 2021 — Dec 2021 [monthly]

    Completed NA

  2. Sep 2020 — Jan 2021 [monthly]

    Completed NA

  3. Jun 2018 — Sep 2020 [monthly]

    Completed NA

  4. Feb 2017 — Jun 2018 [monthly]

    Completed NA

  5. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations